EXEL Profile
Exelixis, Inc. operates as a biotechnology firm dedicated to advancing oncology treatments through innovative drug discovery, development, and commercialization efforts primarily in the United States. The company's portfolio includes CABOMETYX tablets, approved for patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy, and COMETRIQ capsules, indicated for progressive and metastatic medullary thyroid cancer. Both medications are derived from cabozantinib, a potent inhibitor targeting multiple tyrosine kinases such as MET, AXL, RET, and VEGF receptors.
In addition to CABOMETYX and COMETRIQ, Exelixis offers COTELLIC, a MEK inhibitor used in combination therapies for advanced melanoma, and MINNEBRO, a selective blocker of the mineralocorticoid receptor approved for treating hypertension in Japan. The company continues to expand its pipeline with promising candidates like zanzalintinib, an oral tyrosine kinase inhibitor addressing VEGF receptors and other kinases crucial in cancer growth and spread.
Exelixis is actively involved in developing next-generation therapies such as XB002, an antibody-drug conjugate targeting tissue factor for advanced solid tumors, and XL102, a cyclin-dependent kinase 7 (CDK7) inhibitor aimed at treating advanced or metastatic solid tumors. The company's collaborative efforts include strategic partnerships with leading pharmaceutical firms like Ipsen Pharma, Takeda Pharmaceutical, and Roche, among others, enhancing its capabilities in drug development and clinical research.
Founded in 1994 and headquartered in Alameda, California, Exelixis, Inc. has evolved significantly since its inception as Exelixis Pharmaceuticals, Inc., reflecting its commitment to pioneering advancements in oncology treatments. With a robust pipeline and extensive network of research collaborations and licensing agreements, Exelixis remains at the forefront of innovation, dedicated to improving outcomes for patients battling cancer worldwide.
|
